Research programme: complement factor 5a inhibitors - Neurogen
Alternative Names: Research programme: C5a receptor inhibitors - NeurogenLatest Information Update: 06 Jul 2010
At a glance
- Originator Neurogen Corporation
- Class Small molecules
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 06 Jul 2010 Development discontinued during 2008
- 25 Apr 2007 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 16 Jun 2004 This programme is still in active development